Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
Conditions
Brief summary
This phase I/II trial investigates the side effects of genetically engineered cells called FH-MagIC TCR-T cells and how well they work with atezolizumab in treating patients with triple negative breast cancer, urothelial cancer, or non-small cell lung cancer that has spread to other places in the body (metastatic). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize MAGE-A1, a protein on the surface of tumor cells. These MAGE-A1-specific T cells may help the body's immune system identify and kill MAGE-A1 tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FH-MagIC TCR-T cells with atezolizumab may help treat patients with triple negative breast cancer, urothelial cancer, or non-small cell lung cancer.
Detailed description
OUTLINE: This is a phase I, dose escalation study of FH-MagIC TCR-T cells followed by a phase II study. LYMPHODEPLETION: Patients receive cyclophosphamide intravenously (IV) and fludarabine IV on days -4, -3, and -2 before each T-cell infusion. T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion. In the Phase 2 portion of the study, atezolizumab will be administered as standard of care beginning 24-72 hours after T-cell infusion. Atezolizumab will be given IV every 3 weeks for at least 1 year in the absence of disease progression or unacceptable toxicity. An alternative PD1 inhibitor may be substituted if atezolizumab (preferred) is not available. After completion of study treatment, patients are followed up annually for 15 years after final infusion of FH-MagIC TCR-T.
Interventions
DRUGAtezolizumab
Given IV
DRUGCyclophosphamide
Given IV
DRUGFludarabine
Given IV
BIOLOGICALMAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
Given IV
BIOLOGICALPD1 Inhibitor
Given IV
Sponsors
SignalOne Bio, Inc.
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Tissue confirmation of triple negative breast cancer (TNBC), urothelial carcinoma or non-small cell lung cancer (NSCLC) and expression of MAGEA1: Participants must have metastatic disease. Confirmation of diagnosis must be or have been performed by internal pathology review of archival, initial or subsequent biopsy or other pathologic material at Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA)/University of Washington Medical Center (UWMC). Patients with TNBC must meet the American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) definition of negative estrogen, progesterone and HER2 receptor expression. Baseline tissue will be stained to confirm MAGE-A1 expression * Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as \>= 10 mm, unless lymph node in which case short axis must be \>= 15 mm. Baseline imaging (for example diagnostic computed tomography \[CT\] chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain imaging (magnetic resonance imaging \[MRI\] or CT scan) must be obtained within 45 days of prior to start of first planned FH-MAGEA1-A2TCR infusion. MRI can be substituted for CT in patients unable to have CT contrast. Measurable disease is not required for purposes of leukapheresis /cell manufacturing storage for patients who meet HLA and expression criteria but not standard treatment criteria * Previous treatment with standard of care (SOC) Food and Drug Administration (FDA)-approved therapies. Patients with NSCLC who have actionable somatic mutations or alterations in EGFR, ROS1 and ALK with FDA-approved drug therapy options will be eligible for study only after treatment with targeted therapies for those mutations have been offered or received. Patients with urothelial carcinoma who are candidates for enfortumab vedotin (enfortumab vedotin-ejfv) will be eligible for study after prior treatment with enfortumab vedotin-ejfv has been offered or received \* Note: Participants will be eligible to enroll before standard therapy is received in order to expedite leukapheresis/cell manufacturing as long as the aforementioned agent is administered prior to lymphodepletion and/or cell infusion * Previous treatment with PD-1 axis inhibitor: Patients in Phase I/2 must have been offered or been previously treated with at least one dose of a PD-L1 axis inhibitor (e.g. PD-1 or PD-L1 inhibiting monoclonal antibody such as pembrolizumab, nivolumab, avelumab, atezolizumab, durvalumab). If received, they must have either developed progression or still have detectable disease and not have developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher toxicity while on treatment. Patients may have received 1 or more prior systemic regimens for metastatic TNBC or NSCLC. There is no upper limit on prior regimens. Patients may have received prior anti-PD-1/anti-PD-L1 in the neoadjuvant or adjuvant setting * HLA type HLA-A\*02:01: Participants must be HLA-A\*02:01 in order for infused transgenic T cells in order to insure recognition of antigen-MHC complexes. HLA typing should be determined though a molecular approach in a clinical laboratory licensed for HLA typing * Life expectancy must be anticipated to be \> 3 months at trial entry * 18 years or older * Capable of understanding and providing a written informed consent * If fertile, willingness to comply with reproductive requirements * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Tumor tissue amenable to safe biopsy and subject willing to undergo serial tumor biopsies: Should there be no tumor tissue that is accessible for biopsy, patients will still be considered for participation, at discretion of the sponsor and in consultation with the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons biopsies may be cancelled or retimed after confirming plan with the sponsor * Participants must be at least three weeks from last systemic treatment at the time of cell collection: At least 3 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), small molecule or chemotherapy cancer treatment, other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates are permitted but the concurrent treatment with RANK ligand inhibitors (i.e., denosumab) is not permitted within 8 weeks of treatment * Serum creatine \< 2.5 mg/dL or estimated glomerular filtration rate (eGFR) \> 30 mL/min * Total bilirubin (tBili) \< 3.0 mg/dL. Patients with suspected Gilbert syndrome may be included if Tbili \> 3 but no other evidence of hepatic dysfunction * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x upper limit of normal (ULN) * =\< grade 1 dyspnea and oxygen saturation (SaO2) \>= 92% on ambient air. If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, patients with forced expiratory volume in 1 second (FEVI) \>= 50% of predicted and carbon monoxide diffusing capability test (DLCO) (corrected) of \>= 40% of predicted will be eligible * Patients 60 years of age or older are required to have left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be established with echocardiogram or multigated acquisition scan (MUGA) scan, and left ejection fraction must be \>= 35%. Cardiac evaluation for other patients is at the discretion of the treating physician * Absolute neutrophil count (ANC) \> 500 cells/ mm\^3
Exclusion criteria
* Expression of HLA B\*4901: participants will be excluded due to the risk of alloreactivity * Participants of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment. Childbearing potential is defined as women who have not been surgically sterilized and who are not postmenopausal (free of menses for at least 1 year) * Patients with active autoimmune disease requiring immunosuppressive therapy are excluded. Case-by-case exemptions are possible with approval by principal investigator (PI) * Prior solid organ transplant or allogenic hematopoietic stem cell transplant: Kidney transplant patients will be considered on a case-by-case basis requiring discussion with PI. If kidney transplant, patient must have dialysis access, dialysis plan, supportive nephrologist, willingness to stop transplant immunosuppression, and express understanding that rejection is possible outcome. Dialysis or costs related to transplant kidney will not be supported by the study. Participants having had any other solid organ transplants will be excluded, as will those with any history of allogeneic stem cell transplant * Corticosteroid therapy at a dose equivalent of \> 0.5 mg/kg of prednisone-equivalent per day * Concurrent use of other investigational anti-cancer agents * Chronic lymphocytic leukemia (CLL) or other active hematologic malignancy * Active uncontrolled infection: Human immunodeficiency virus (HIV) positive participants on highly active anti-retroviral therapy (HAART) with a CD4 count \> 500 cells/mm\^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have, per standard practice, hepatitis well-controlled on medication (e.g., AST and ALT \< 5 x ULN) * Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Participants with small asymptomatic brain metastases (\< 1 cm) or those with brain metastases previously treated with surgery or radiotherapy will be considered for inclusion at discretion of principal investigator, so long as other eligibility criteria are met. * For patients in phase 1/2, grade 3 or higher immune-mediated toxicity to any prior PD-L1 axis blocking agent * Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of up to 0.5 mg/kg prednisone per day, unless otherwise approved by PI * Study participants must not have significant active underlying neurologic disease, unless approved by PI. Neuropathy related to diabetes or prior chemotherapy is acceptable * Other medical, social, or psychiatric factor that interferes with medical appropriateness and/or ability to comply with study, as determined by the PI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Count of Participants That Experienced Treatment-related Unexpected Grade 3 or Higher Adverse Events | 4 weeks post last infusion per patient | — |
| Best Overall Response | 1 year post infusion | Lesions will be separately tracked but response determined in totality. As indicated, patient must have at least one trackable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Response will be a defined as best overall response by RECIST 1.1. A Complete Response will be defined as total regression of all tumors, a Partial Response as 30% or greater decrease in the sum of the longest diameter of target lesions compared to baseline and Progressive Disease as 20% increase in the sum of the longest diameter of target lesions compared to the smallest prior diameter. If the disease does not fall in either category it will be considered Stable Disease (RECIST v1.1 criteria). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | 1 year post infusion | Outcome will be reported as a count of participants that were alive as the 1 year post infusion timepoint and also had not experienced progression at that timepoint. |
| Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | 1 year post infusion | Results will be reported by sample for the single treated patient. Patient samples were tested using a WPRE assay showing transgenic T cells in blood. This was detected by qPCR. |
| Objective Response Rates | 1 year post infusion | Evaluated by immune-related RECIST criteria. Outcome will be reported as a count of participants that experienced a Complete Response or Partial Response per RECIST criteria. A complete response (CR) will be defined as total regression of all tumors, a Partial Response as 30% or greater decrease in the sum of the longest diameter of target lesions compared to baseline and Progressive Disease as 20% increase in the sum of the longest diameter of target lesions compared to the smallest prior diameter. If the disease does not fall in either category it will be considered Stable Disease (RECIST v1.1 criteria). |
| Overall Survival | 1 year post infusion | Outcome will be reported as a count of participants that were alive at the 1 year post infusion timepoint. |
| Participants That Displayed Transgenic T Cells in Tumor Tissue | 1 year post infusion | Outcome will be reported as a count of participants that displayed transgenic T cells in their tumor tissue after treatment. This was assessed by WRPE staining and scRNA sequencing. Unfortunately, no transgenic cells were detected on the one treated patient's tumors. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) LYMPHODEPLETION: Patients receive cyclophosphamide IV and fludarabine IV on days -4, -3, and -2 before each T-cell infusion.
T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion.
In the Phase 2 portion of the study, atezolizumab will be administered as standard of care beginning 24-72 hours after T-cell infusion. Atezolizumab will be given IV every 3 weeks for at least 1 year in the absence of disease progression or unacceptable toxicity. An alternative PD1 inhibitor may be substituted if atezolizumab (preferred) is not available.
Atezolizumab: Given IV
Cyclophosphamide: Given IV
Fludarabine: Given IV
MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells: Given IV
PD1 Inhibitor: Given IV | 1 |
| Total | 1 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 1 |
Baseline characteristics
| Characteristic | Treatment (FH-MagIC TCR-T Cells, Atezolizumab) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Region of Enrollment United States | 1 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 1 |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
Best Overall Response
Lesions will be separately tracked but response determined in totality. As indicated, patient must have at least one trackable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Response will be a defined as best overall response by RECIST 1.1. A Complete Response will be defined as total regression of all tumors, a Partial Response as 30% or greater decrease in the sum of the longest diameter of target lesions compared to baseline and Progressive Disease as 20% increase in the sum of the longest diameter of target lesions compared to the smallest prior diameter. If the disease does not fall in either category it will be considered Stable Disease (RECIST v1.1 criteria).
Time frame: 1 year post infusion
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Best Overall Response | Complete response | 0 Participants |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Best Overall Response | Partial response | 0 Participants |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Best Overall Response | Stable disease | 1 Participants |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Best Overall Response | Progressive disease | 0 Participants |
Primary
Count of Participants That Experienced Treatment-related Unexpected Grade 3 or Higher Adverse Events
Time frame: 4 weeks post last infusion per patient
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Count of Participants That Experienced Treatment-related Unexpected Grade 3 or Higher Adverse Events | 0 Participants |
Secondary
Objective Response Rates
Evaluated by immune-related RECIST criteria. Outcome will be reported as a count of participants that experienced a Complete Response or Partial Response per RECIST criteria. A complete response (CR) will be defined as total regression of all tumors, a Partial Response as 30% or greater decrease in the sum of the longest diameter of target lesions compared to baseline and Progressive Disease as 20% increase in the sum of the longest diameter of target lesions compared to the smallest prior diameter. If the disease does not fall in either category it will be considered Stable Disease (RECIST v1.1 criteria).
Time frame: 1 year post infusion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Objective Response Rates | 0 Participants |
Secondary
Overall Survival
Outcome will be reported as a count of participants that were alive at the 1 year post infusion timepoint.
Time frame: 1 year post infusion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Overall Survival | 0 Participants |
Secondary
Participants That Displayed Transgenic T Cells in Tumor Tissue
Outcome will be reported as a count of participants that displayed transgenic T cells in their tumor tissue after treatment. This was assessed by WRPE staining and scRNA sequencing. Unfortunately, no transgenic cells were detected on the one treated patient's tumors.
Time frame: 1 year post infusion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Participants That Displayed Transgenic T Cells in Tumor Tissue | 0 Participants |
Secondary
Peripheral Blood Concentration of Infused Transgenic T Cells Over Time
Results will be reported by sample for the single treated patient. Patient samples were tested using a WPRE assay showing transgenic T cells in blood. This was detected by qPCR.
Time frame: 1 year post infusion
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D028 | 0.0087 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712PRETX | 0.0 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D000 | 0.0 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D001 | 0.0101 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D003 | 0.0303 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D007 | 0.0379 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D014 | 0.0379 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D021 | 0.0111 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D056 | 0.0107 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I1D180 | 0.0062 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D03 | 0.1167 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D07 | 0.0795 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D14 | 0.0353 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D21 | 0.0267 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D28 | 0.0333 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D56 | 0.0027 WPRE copies/Cell |
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Peripheral Blood Concentration of Infused Transgenic T Cells Over Time | BU712I2D84 | 0.0070 WPRE copies/Cell |
Secondary
Progression-free Survival
Outcome will be reported as a count of participants that were alive as the 1 year post infusion timepoint and also had not experienced progression at that timepoint.
Time frame: 1 year post infusion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (FH-MagIC TCR-T Cells, Atezolizumab) | Progression-free Survival | 0 Participants |